Human Reticulon-4(RTN4) ELISA kit

Instructions
Code CSB-EL020572HU
Size 96T,5×96T,10×96T
See More Details 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name reticulon 4
Alternative Names 1110020G17Rik ELISA Kit; AA407876 ELISA Kit; AA409940 ELISA Kit; AA960376 ELISA Kit; ASY ELISA Kit; C130026I10Rik ELISA Kit; Foocen ELISA Kit; Glut4 vesicle 20 kDa protein ELISA Kit; Human NogoA ELISA Kit; Kiaa0886 ELISA Kit; KIAA4153 ELISA Kit; MGC116054 ELISA Kit; MGC139261 ELISA Kit; mKIAA0886 ELISA Kit; mKIAA4153 ELISA Kit; My043 protein ELISA Kit; Nbla00271 ELISA Kit; Nbla10545 ELISA Kit; Neurite growth inhibitor 220 ELISA Kit; Neurite Growth Inhibitor 220, included ELISA Kit; Neurite outgrowth inhibitor ELISA Kit; Neuroendocrine-specific protein ELISA Kit; Neuroendocrine-specific protein C homolog ELISA Kit; NI-250 ELISA Kit; NI220/250 ELISA Kit; Nogo A ELISA Kit; NOGO ELISA Kit; Nogo B ELISA Kit; Nogo C ELISA Kit; Nogo protein ELISA Kit; NOGOC ELISA Kit; NSP ELISA Kit; NSP-CL ELISA Kit; rat N ELISA Kit; Reticulon 4 ELISA Kit; Reticulon 5 ELISA Kit; Reticulon-4 ELISA Kit; Reticulon-5 ELISA Kit; RTN X ELISA Kit; RTN-x ELISA Kit; Rtn4 ELISA Kit; Rtn4 reticulon 4 ELISA Kit; RTN4-A ELISA Kit; RTN4-B1 ELISA Kit; RTN4-B2 ELISA Kit; RTN4-C ELISA Kit; RTN4_HUMAN ELISA Kit; Vp20 ELISA Kit
Abbreviation RTN4
Uniprot No. Q9NQC3
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates
Detection Range 46.88 pg/mL-3000 pg/mL
Sensitivity 11.75 pg/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Neuroscience
Assay Principle quantitative
Measurement Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%        
Three samples of known concentration were tested twenty times on one plate to assess.    
Inter-assay Precision (Precision between assays): CV%<10%        
Three samples of known concentration were tested in twenty assays to assess.      
               
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human RTN4 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.  
  Sample Serum(n=4)    
1:1 Average % 97    
Range % 92-101    
1:2 Average % 92    
Range % 88-96    
1:4 Average % 89    
Range % 84-93    
1:8 Average % 96    
Range % 91-100    
Recovery
The recovery of human RTN4 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.  
 
Sample Type Average % Recovery Range    
Serum (n=5) 103 99-108    
EDTA plasma (n=4) 84 80-88    
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.  
 
pg/ml OD1 OD2 Average Corrected    
3000 2.664 2.728 2.696 2.502    
1500 2.120 1.994 2.057 1.863    
750 1.200 1.251 1.226 1.032    
375 0.753 0.785 0.769 0.575    
187.5 0.439 0.462 0.451 0.257    
93.75 0.315 0.307 0.311 0.117    
46.88 0.247 0.239 0.243 0.049    
0 0.191 0.196 0.194      
Troubleshooting
and FAQs
ELISA kit FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 5-7 working days

Target Data

Function Developmental neurite growth regulatory factor with a role as a negative regulator of axon-axon adhesion and growth, and as a facilitator of neurite branching. Regulates neurite fasciculation, branching and extension in the developing nervous system. Involved in down-regulation of growth, stabilization of wiring and restriction of plasticity in the adult CNS. Regulates the radial migration of cortical neurons via an RTN4R-LINGO1 containing receptor complex (By similarity). Isoform 2 reduces the anti-apoptotic activity of Bcl-xl and Bcl-2. This is likely consecutive to their change in subcellular location, from the mitochondria to the endoplasmic reticulum, after binding and sequestration. Isoform 2 and isoform 3 inhibit BACE1 activity and amyloid precursor protein processing. Induces the formation and stabilization of endoplasmic reticulum (ER) tubules
Gene References into Functions
  1. This review aims at presenting our current knowledge on the role of Nogo-A in the visual system and to discuss how its therapeutic targeting may promote visual improvement in ophthalmic diseases. PMID: 28408340
  2. CAA and TATC Insertion/Deletion Genetic Polymorphisms of RTN4 3'-UTR are associated with Hepatocellular Carcinoma PMID: 28144881
  3. Nogo-B was shown to play an important negative role in apoptotic signaling through its interaction with c-FLIP in colorectal cancer cells. PMID: 29684585
  4. NOGO-B/RTN4B and NOGO-A/RTN4A are simultaneously expressed in cultured epithelial, fibroblast and neuronal cells. Morphological analysis of cells with manipulated levels of NOGO-B/RTN4B revealed that it is required for maintenance of normal endoplasmic reticulum shape. PMID: 27786289
  5. Nogo-B is expressed aberrantly in HCCs and plays an oncogenic role. These findings support that Nogo-B may be a novel anti-HCC therapeutic target. PMID: 28628795
  6. observations suggest that Rtn4A counteracts the Nrdp1-mediated degradation of ErbB3 by sequestering the ubiquitin ligase into ER tubules. PMID: 27353365
  7. NOGO-A/B may be a negative prognostic factor of malignant melanoma. PMID: 27354599
  8. LILRA3 significantly reversed Nogo-66-mediated inhibition of neurite outgrowth and promoted synapse formation in primary cortical neurons through regulation of the ERK/MEK pathway. PMID: 26826187
  9. Nogo-B expression is down-regulated in intrahepatic cholangiocarcinoma, the implication of which, however, remains to be investigated. PMID: 26656426
  10. Data show that the mean peak serum neuroglobin and Nogo-A concentrations were both significantly higher in patients with an unfavorable outcome at 6 months after traumatic brain injury (TBI). PMID: 26472601
  11. RTN4-C knockdown blocks cell cycle progression and cell growth in colorectal cancer cell lines. PMID: 25847052
  12. Epithelial RTN-4B/NOGO-B was downregulated in human and experimental inflammatory bowel disease PMID: 25907690
  13. The Nogo-B-PirB axis controls macrophage-mediated vascular remodeling. PMID: 24278366
  14. a novel mechanism that functionally couples cAMP signaling with the proteolytic turnover of NOGO-A, positively impacting on neurite outgrowth in mammalian brain. PMID: 25331889
  15. The RTN4 del allele could significantly increase NSCLC risk. PMID: 25040983
  16. Identify Nogo-C as a tumor suppressor gene in hepatocellular carcinoma and B-raf as a novel interacting protein. PMID: 24966913
  17. the present study found that Nogo-A depletion was capable of inhibiting HCC SMMC-7721 cell proliferation by promoting G2/M cell cycle arrest and apoptosis. PMID: 24626842
  18. The expression of Nogo-B, in arterial intima, is impeded in the early stages of atherosclerosis. Macrophage infiltration is not accompanied by Nogo-B expression in atherosclerotic arteries. PMID: 24372562
  19. Nogo-A/B expression decreased with increasing squamous cell carcinoma malignancy grade (p=0.026). PMID: 25075030
  20. Neither migration speed, nor cell proliferation, or layer area sizes were influenced by Nogo-A deletion, hence suggesting another role for early postnatal Nogo-A expression in the premigratory zone of the external granule layer. PMID: 24401759
  21. knockdown of NgR enhanced invasion and adhesion but increased cell apoptosis in C6 cells, suggesting that Nogo-66/NgR might have complex effects on glioma cells. PMID: 23982337
  22. Studied premenopausal women with uterine leiomyoma. No significant association was observed between the TATC in/del polymorphism and UL risk, but increased UL risk was associated with CAA in/del polymorphism in the recessive and codominant model. PMID: 23479081
  23. Overexpression of Nogo-B promotes the epithelial-mesenchymal transition in cervical cancer via Fibulin-5. PMID: 23042479
  24. The absence of Nogo-B enhances apoptosis of hepatic stellate cells in experimental cirrhosis. PMID: 23313137
  25. The results demonstrate a significant change in the expression of Nogo-A during the development of the human brain PMID: 23146900
  26. CAA and TATC insertion/deletion polymorphisms of RNT4 gene may not be a useful marker to predict the susceptibility of ASD in Chinese Han population PMID: 22313113
  27. genetic variation in RTN4 3'-UTR contributes to the susceptibility to CSCC PMID: 22320844
  28. The presence of Nogo-A in diseased human muscle biopsies is not limited to ALS, therefore it cannot be the standard for ALS diagnosis. PMID: 21503119
  29. Nogo-A is a useful marker for the diagnosis of oligodendroglioma and for identifying 1p19q codeletion PMID: 21835431
  30. Nogo receptor 3, a paralog of NgR1,functions as a NgR1 co-receptor for Nogo-66. PMID: 22133682
  31. The data identify, for the first time, an effect of Nogo B in the brain and specifically show that its expression is increased in conditions where synaptic plasticity is compromised. PMID: 21111015
  32. Data showd that Nogo-B, a regulator of ER structure, was induced by hypoxia in pulonary artery smooht muscle cells but not the systemic vasculature through activation of the ER stress-sensitive transcription factor ATF6. PMID: 21697531
  33. A multi-domain fragment of Nogo-A protein is a potent inhibitor of cortical axon regeneration via Nogo receptor 1. PMID: 21454605
  34. No significant differences in 3'UTR TATC and CAA insertion/deletion polymorphism genotype and allele frequencies were observed between the ventricular septal defect patients and controls. PMID: 21166502
  35. Nogo-A is highly expressed in oligodendroglial tumors; however, it does not serve as a definite marker specific for oligodendroglial tumors PMID: 20487307
  36. Endogenous Nogo-B, which may exert its effects through ARPC 2/3 and MYL-9, is necessary for the migration and contraction of airway smooth muscle cells. PMID: 21251247
  37. Using leukocytes and endothelial cells, we show mechanistically that the silencing of Nogo-B with siRNA impairs the transmigration of neutrophils and reduces ICAM-1-stimulated phosphorylation of VE-cadherin. PMID: 21183689
  38. These results suggest a role for neuronal Nogo-A in maintaining a spine phenotype in neocortical pyramidal cells PMID: 20938157
  39. Nogo-B may regulate macrophage recruitment after unilateral ureteral obstruction, although it does not greatly affect the degree of tissue injury or fibrosis in this model. PMID: 20971739
  40. Reticulons, the only molecular so far to participate in all three apoptosis signaling pathways, may be a novel player in the progress of atherosclerosis. PMID: 20717916
  41. Epithelial reticulon 4B (Nogo-B) is an endogenous regulator of Th2-driven lung inflammation. PMID: 20975041
  42. Fibulin-5, a secreted extracellular matrix protein, was identified as a binding partner of Nogo-B. PMID: 20599731
  43. verified the molecular interaction of Nogo-A with 2', 3'-cyclic nucleotide 3'-phosphodiesterase (CNP), which could act as a conformational stabilizer for the intrinsically unstructured large segment of Amino-Nogo PMID: 19508346
  44. identified Akt1 as a new signaling component of the amino-Nogo pathway. Akt1 phosphorylation is decreased by amino-Nogo. PMID: 20018888
  45. An RTN4-C mutant lacking the C-terminal domain bound to BACE1 comparably to wild-type RTN4-C & reduced Abeta40 & Abeta42 secretion by cells expressing Swedish mutant APP. PMID: 19405102
  46. The alteration in Nogo gene expression in muscle biopsy represents a potential diagnostic tool for the early stages of amyotrophic lateral sclerosis. PMID: 12270696
  47. Elevated expression of Nogo mRNA in schizophrenia was confirmed by RT-PCR. Nogo mRNA was found to contain a CAA insert polymorphism in the 3'-untranslated region. PMID: 12425946
  48. results describe the regulation of nogo expression through its promoter region PMID: 12488097
  49. ASY may be multi-functional, regulating apoptosis, tumor development, and neuronal regeneration [review] PMID: 12510146
  50. ER stress of highly overexpressed Nogo-B may lead to aversive cellular reactions under particular conditions. Our data do not support a function of Nogo-B as a physiological pro-apoptotic protein in certain types of cancer. PMID: 12618765
  51. ASYIP(ASY-interacting) protein co-localized with ASY in endoplasmic reticulum. Characterization of ASYIP gene may help clarify mechanism of ASY-induced apoptosis or Nogo-involved inhibition of neuronal regeneration in central nervous system. PMID: 12811824
  52. this study found a similar frequency of the CAA insertion for patients and controls in both populations, but a large difference in CAA insertion frequency between the European American and the African American. PMID: 14741411
  53. Nogo-B is a regulator of vascular homeostasis and remodeling broadens the functional scope of this family of proteins PMID: 15034570
  54. The steady-state level of reticulon 4-B mRNA was shown to be up-regulated by pressure, but not by mechanical stretch; close association with endoplasmic reticulum PMID: 15147731
  55. In temporal lobe epilepsy Nogo-A mRNA and immunoreactivity were markedly up-regulated in most neurons and their processes throughout the hippocampal formation. PMID: 15245492
  56. Expression of the genes encoding Nogo and its receptor, NgR, between weeks eight and 23 of human embryonic development PMID: 15749087
  57. Nogo CAA 3'UTR insertion polymorphism is not associated with schizophrenia or bipolar disorder PMID: 15820318
  58. There was a statistically significant difference at the allelic level for both the CAA (chi2 = 4.378, df = 1, P value = 0.036) and TATC (chi2 = 5.807, df = 1, P = 0.016) polymorphisms in the female subgroup. PMID: 15953657
  59. results identify Nogo-B as a new physiological substrate of MAPKAP-K2 PMID: 16095439
  60. Nogo-A is possibly the best characterized of a variety of neurite growth inhibitors present in CNS myelin--REVIEW PMID: 16629624
  61. ASY/Nogo gene may act as a suppressor against adult T-cell leukemia/lymphoma progression, independent of Tax expression PMID: 16646068
  62. Reticulon proteins such as Nogo-A participate in the neuronal responses stemming from hippocampal formation during senescence, and particularly in Alzheimer disease . PMID: 16772867
  63. identify a previously uncharacterized Nogo-B receptor specific for the amino terminus of Nogo-B PMID: 16835300
  64. identify a previously uncharacterized Nogo-B receptor specific for the amino terminus of Nogo-B. PMID: 16835300
  65. Expressed in HEK293 cells, Nogo-C confers apoptosis by inducing caspase-3 and p53 activation through the c-jun N-terminal kinase-c-Jun-dependent pathway. PMID: 16905119
  66. Results describe the mapping of interaction domains mediating binding between BACE1 and RTN3/Nogo proteins. PMID: 16979658
  67. Nogo C to be overexpressed by 26% in the schizophrenia tissues And Nogo B was reduced by 17% in the frontal cortices who had severe depression. PMID: 17022955
  68. Data show that the C-terminal of Nogo protein interacts with CX26. PMID: 17029193
  69. Soluble Nogo-A may be specific for the cerebrofinal fluid of patients with multiple sclerosis and may predict failure of axonal regeneration in the central nervous system. PMID: 17242333
  70. systematic substitution analysis of all 6 Cys residues of Nogo-A indicated that this domain forms 2 structural disulfide bonds among Cys residues 424, 464, 559 & 597, whereas the Cys residues at positions 699 & 912 seem to be dispensable for folding. PMID: 17437522
  71. The detection of Nogo-A in muscle biopsy samples from LMNS patients correctly identified patients who further progressed to ALS with 91% accuracy, 94% sensitivity, and 88% specificity. PMID: 17455292
  72. Nogo-A expression was negatively correlated with the malignancy grade of oligodendroglial tumors. PMID: 17592524
  73. The presence of Nogo-A in diseased human muscle biopsies is not limited to amyotrophic lateral sclerosis. PMID: 17626519
  74. Reduction of Nogo-B protein expression in thoracic aortic aneurysms is closely correlated to the formation of aneurysm and that Nogo-B may play a protective role in the pathological process of aneurysms. PMID: 17645629
  75. Accordingly, two novel mechanisms, A beta PP overexpression and ER stress, are involved in Nogo-B and Nogo-A expression in human muscle. PMID: 17764014
  76. Data is the first report to demonstrate the relationship between Nogo expression and heart failure, including cell-type specificity, in human HF and phenotypic rescue. PMID: 17971502
  77. found A172G (Thr58Ala), A340G (Arg114Gly), A571G (Ile191Val) mutations of Nogo-C in hepatocellular carcinoma patients from Qidong in China PMID: 18080785
  78. Inhibition of integrin signaling by Amino-Nogo (nucleotide fragment 540-2592) contributes to the failure of central nervous system axon regeneration. PMID: 18234903
  79. A 25 kD band is detectable on Western blots stained with Nogo-A antibody in almost all CSF specimens, but is not likely to be a useful biomarker for multiple sclerosis. PMID: 18495952
  80. Nogo-a expression in glial CNS tumors may be a marker to differentiate between oligodendrogliomas and other gliomas. PMID: 18685489
  81. RTN4 allele (TATC)(2) and (TATC)(2)/(TATC)(2) genotype are associated with DCM. PMID: 18948092
  82. analysis of the interaction between ubiquitin ligase WWP1 and Nogo-A PMID: 19035836
  83. Phosphorylation of Nogo receptors by casein kinase II (CK2) inhibits binding of the myelin-associated proteins. PMID: 19336839
  84. A Nogo deletion mutant mouse line created via Cre-loxP-mediated recombination is confirmed to be a complete Nogo null allele, lacking expression of all known Nogo isoforms. PMID: 19587271
  85. findings suggest that fibroatheroma progression is inversely associated with Nogo-B expression PMID: 19654939
  86. In a transgenic mouse model of amyotrophic lateral sclerosis (ALS), Nogo-A contributes to the proper function of the resident endoplasmic reticulum chaperone protein disulfide isomerase, and is protective against ALS-like neurodegeneration. PMID: 19889996
  87. There is a direct correlation between the expression of Nogo A and C and the presence of alleles with a CAA insert in 3' UTR. New sample group shows Nogo C upregulation in schizophrenia and Nogo B downregulation in depression. PMID: 17022955

Show More

Hide All

Subcellular Location Endoplasmic reticulum membrane, Multi-pass membrane protein
Tissue Specificity Isoform 1 is specifically expressed in brain and testis and weakly in heart and skeletal muscle. Isoform 2 is widely expressed except for the liver. Isoform 3 is expressed in brain, skeletal muscle and adipocytes. Isoform 4 is testis-specific.
Database Links

HGNC: 14085

OMIM: 604475

KEGG: hsa:57142

STRING: 9606.ENSP00000337838

UniGene: Hs.637850

Most popular with customers

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1